Slide 1: FY20 Results Investor Presentation
FY20 Results Investor Presentation 26 August 2020
Slide 2: Executive Summary
Executive Summary 2 • Total revenue of $15.9m, up 12% on pcp (FY19: $14.2m) • Services revenue of $14.9m1, up 12% on pcp (FY19: $13.3m) FY20 Results • Cash operating loss2 of $79k, a significant improvement on $1.95m loss in FY19 • Cost reduction initiatives within the core business, implemented due
Slide 3: Hydrix – Business Overview
Hydrix – Business Overview 3 Hydrix is leveraging its powerful product innovation capability to capture more of the value it creates across multiple growth platforms Hydrix Services Hydrix Ventures Hydrix Medical Product Design & Engineering Services Direct & ‘Equity for Service’ Investments Tech-ri
Slide 4: FY20 Results
FY20 Results 4 Continuing to deliver revenue growth in a challenging environment whilst diligently managing expenses Profit & Loss Key Insights Profit & Loss Hydrix Hydrix Hydrix Hydrix FY20 FY19 • FY20 Services revenue of $14.9m, up 12% on pcp (FY19: $13.3m) $000's Services Ventures Medical Limited
Slide 5: Hydrix Services: Global Expertise In Large & Growing Sectors
Hydrix Services: Global Expertise In Large & Growing Sectors 5 Creating leading products & innovations that transform markets Medical Technologies Industrial & Mining Defence & Rail Portable X-Ray Machine Mining Defence Training Hydrix was the primary Hydrix is driving technology Hydrix is providing
Slide 6: Hydrix Medical - Overview
Hydrix Medical - Overview 6 Hydrix Medical’s mission is to identify and distribute technology-rich cardiovascular products in Asia-Pacific markets that will: • Improve patient quality of life and well-being • Provide a greater sense of freedom & mobility Our commitment is to ensure we exceed our cus
Slide 7: Hydrix Medical - 1st Portfolio Product: The AngelMed Guardian
Hydrix Medical - 1st Portfolio Product: The AngelMed Guardian® 7 World’s first FDA approved implantable heart attack alert system using patented AI & Machine Learning algorithms – FDA approved 1st generation device in April 2018 – Undertaking FDA approval for upgraded longer-life battery (2x) for co
Slide 8: AngelMed Guardian – First Implants in Asia Pacific completed, a great team effort
AngelMed Guardian – First Implants in Asia Pacific completed, a great team effort 8 Dr Leslie Lam and his surgical team, together with Hydrix Medical Field Clinical Engineer, Ng Ai Wee, gather on completion of the successful implants.
Slide 9: AngelMed Guardian – All four patients have now successfully been discharged
AngelMed Guardian – All four patients have now successfully been discharged 9 4 implants approved under GN26 ‘special access’ scheme in Singapore have now been accomplished Ng Ai Wee, Hydrix Medical Field Clinical Engineer, with one of the first recipients of an AngelMed Guardian in Singapore
Slide 10: Large Market Opportunity for the AngelMed Guardian
Large Market Opportunity for the AngelMed Guardian® 10 Potential Market Penetration Annual Sales Volume (units) Annual Sales Value (A$)3 Region1 Population (m) ACS Incidences p.a. 2 1.0% 5.0% 1.0% 5.0% Australia 25.1 75,000 750 3,750 $5.6m $28.1m Initial Target Singapore 5.7 30,000 300 1,500 $2.2m $
Slide 11: Hydrix Medical – vision for Cardiac Patient Care
Hydrix Medical – vision for Cardiac Patient Care 11 Patient monitoring Managed Information Clinical Benefits Emergency tracking and alert ‘data’ transmitted through to managed cloud services network Secured data may be stored for later Cardiac monitoring retrieval by GP devices communicate to smart
Slide 12: Hydrix Group – growth leveraged from multiple core platforms
Hydrix Group – growth leveraged from multiple core platforms 12 Significant upside value potential in each of Hydrix’s key growth platforms, each complementing one another Hydrix Services Hydrix Ventures Hydrix Medical Product Design & Engineering Services Direct & ‘Equity for Service’ Investments C
Slide 13: Appendices
Appendices
Slide 14: Hydrix – a corporate snapshot
Hydrix – a corporate snapshot 14 Major Shareholders Shares (m) % Capital Structure (as of 25 August 2020) John W King Nominees & Associates 18.9 17.8% Ticker HYD Jasper Capital P/L (incl. Directors individually) 3.9 3.7% Share Price $0.42 CS Third Nominees (Regal) 3.4 3.2% Shares on Issue (m) 106.2
Slide 15: Board & Senior Management Team
Board & Senior Management Team 15 Hydrix’s board and leadership teams have the experience and drive to ensure the success of the Company Hydrix Board Gavin Coote Paul Wright Joanne Bryant Julie King Alyn Tai Executive Chairman Non-Executive Director Non-Executive Director Non-Executive Director Corp
Slide 16: Disclaimer
Disclaimer This presentation has been prepared by Hydrix Limited (the “Company” or “Hydrix”). This presentation is being provided to investors for the sole purpose of providing preliminary background financial and other information to enable recipients to review the business activities of the Compan
Slide 17: hydrix.com 30-32 Compark Circuit Mulgrave VIC 3170
hydrix.com 30-32 Compark Circuit Mulgrave VIC 3170 Australia ASX:HYD